[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-382458-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-382458-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","understanding-and-targeting-erythroid-progenitor-cells-for-effective-cancer-therapy","Understanding and targeting erythroid progenitor cells for effective cancer therapy","","Tumor-directed aberrant myelopoiesis produces myeloid populations that promote disease. This review focuses on erythroid progenitor cells (EPCs), an underappreciated component of the cancer ecosystem, and explains how altered erythropoiesis supports tumor growth and progression. EPCs show potent pro-tumor effects through growth-factor secretion and immune modulation, while cancers expand EPCs and block their differentiation. Single-cell studies indicate tumor-induced EPCs can transdifferentiate into immunosuppressive myeloid cells, limiting T-cell function and reducing immunotherapy efficacy. The review outlines mechanisms and therapeutic strategies targeting EPC-driven immunosuppression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/understanding-and-targeting-erythroid-progenitor-cells-for-effective-cancer-therapy/382458/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/understanding-and-targeting-erythroid-progenitor-cells-for-effective-cancer-therapy/382458.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do erythroid progenitor cells (EPCs) play in cancer?","Question",{"text":63,"@type":64},"EPCs contribute to tumor progression by secreting growth factors and modulating the immune response, including negative regulation of antitumor immunity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do tumors affect EPC differentiation and expansion?",{"text":68,"@type":64},"Cancers induce strong EPC expansion while suppressing EPC differentiation, promoting a state that supports tumor-promoting functions.",{"name":70,"@type":61,"acceptedAnswer":71},"What do single-cell transcriptome and lineage-tracking studies reveal about EPCs?",{"text":72,"@type":64},"They show that tumor-induced EPCs can transdifferentiate into immunosuppressive myeloid cells, limiting T-cell function and weakening immunotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},382458,1790618472,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","REVIEW  \nUPRI RNIENTON Understanding and targeting erythroid progenitor  \ncells for effective cancer therapy  \nQingfei Wang a,b, Rylee A. Poolea,b and Mateusz Opyrchala,b  \nPurpose of review  \nIt is well described that tumor-directed aberrant myelopoiesis contributes to the generation of various myeloid populations with tumor-promoting properties. A growing number of recent studies have revealed the importance of the previously unappreciated roles of erythroid progenitor cells (EPCs) in the context of cancer, bringing the updated concept that altered erythropoiesis also facilitates tumor growth and progression. Better characterization of EPCs may provide attractive therapeutic opportunities.  \nRecent findings  \nEPCs represent a heterogeneous population. They exhibit crucial pro-tumor activities by secreting growth factors and modulating the immune response. Cancers induce potent EPC expansion and suppress their differentiation. Recent single-cell transcriptome and lineage tracking analyses have provided novel insight that tumor-induced EPCs are able to be transdifferentiated into immunosuppressive myeloid cells to limit T-cell function and immunotherapy. Therapeutic strategies targeting key factors of EPC-driven immunosuppression, reducing the amount of EPCs, and promoting EPC differentiation and maturation have been extensively investigated.  \nSummary  \nThis review summarizes the current state of knowledge as to the fascinating biology of EPCs, highlights mechanisms by which they exert the tumor promoting activities, as well as the perspectives on future directions and strategies to target these cells for potential therapeutic benefit.  \nKeywords  \ncancer, erythroid progenitor cells, erythropoiesis, immunotherapy  \nINTRODUCTION  \nTumor is a heterogeneous and complex ecosystem. The tumor microenvironment contains myriads of stromal cells of hematopoietic and nonhematopoietic developmental origin, such as myeloid cells, T-cells, B cells, natural killer (NK) cells, fibroblasts, pericytes, adipocytes, endothelial cells, and neural cells, which collectively shape the course of the disease and affect therapeutic efficacy of various treatment regimens. Over the past few decades, remarkable progress has been made in understanding the roles of regulatory T-cells (Tregs), myeloidderived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and cancer-associated fibroblasts (CAFs) in cancer progression and response to therapies. Recent studies revealed the importance of the previously unappreciated cell population, erythroid progenitor cells (EPCs), as a negative regulator of antitumor immunity.  \nErythropoiesis is a well orchestrated and strictly regulated process for maintaining a stable number of  \nredbloodcells(RBCs), whichisnecessaryforadequate oxygen transport. Classically, the commitment of hematopoietic stem cells (HSCs) to erythroid cells starts with the differentiation to a multipotent megakaryocyte-erythroid progenitor (MEP) in the bone marrow, followed by a burst-forming erythroid (BFU-E) and colony-forming erythroid (CFU-E) progenitors. Subsequent maturation of CFU-E gives  \naDivision of Hematology/Oncology, Department of Medicine, Indiana  \nUniversity School of Medicine and bIndiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA Correspondence to MateuszOpyrchal, MD, PhD, Division of Hematology/ Oncology, Department of Medicine, Indiana University School of Medicine, C218E, Walther Hall, 980W Walnut St, Indianapolis, IN 46202, USA.  \nTel: +1 317 278 8845; [e-mail: mopyrch@iu.edu](e-mail: mopyrch@iu.edu)  \n[Curr Opin Hematol](Curr Opin Hematol 2023)[ 2023](Curr Opin Hematol 2023), [30:137](30:137)–143  \nDOI:10.1097/MOH.0000000000000762  \nThis is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the wo","cbCaihkyTc9a48jc","https://ap.wps.com/l/cbCaihkyTc9a48jc","pdf",967957,"English","# Purpose of review\n# Recent findings\n# Summary\n# Introduction\n# Main phenotypic and expansion of erythroid progenitor cells in cancer","[{\"question\":\"What role do erythroid progenitor cells (EPCs) play in cancer?\",\"answer\":\"EPCs contribute to tumor progression by secreting growth factors and modulating the immune response, including negative regulation of antitumor immunity.\"},{\"question\":\"How do tumors affect EPC differentiation and expansion?\",\"answer\":\"Cancers induce strong EPC expansion while suppressing EPC differentiation, promoting a state that supports tumor-promoting functions.\"},{\"question\":\"What do single-cell transcriptome and lineage-tracking studies reveal about EPCs?\",\"answer\":\"They show that tumor-induced EPCs can transdifferentiate into immunosuppressive myeloid cells, limiting T-cell function and weakening immunotherapy.\"}]","Understanding and targeting erythroid progenitor cells for effective cancer therapy | PDF",1790250548,18]